Needham & Company Starts Mirati Therapeutics (MRTX) at Hold
Tweet Send to a Friend
Needham & Company analyst Ami Fadia initiates coverage on Mirati ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
